TFF Pharmaceuticals to Present at 23rd H.C. Wainwright Annual Global Investment Conference
TFF Pharmaceuticals, a clinical-stage biopharmaceutical company focused on drug products using Thin Film Freezing technology, announced that President and CEO Glenn Mattes will present a corporate overview at the 23rd H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
TFF Pharmaceuticals, a clinical-stage biopharmaceutical company focused on drug products using Thin Film Freezing technology, announced that President and CEO Glenn Mattes will present a corporate overview at the 23rd H.C. Wainwright Annual Global Investment Conference from September 13-15, 2021.
The presentation will be available on-demand starting at 7:00 a.m. ET on September 13. TFF is known for its drug candidates, including Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder, and holds 58 patents related to its TFF technology.
Details
News Market Reaction – TFFP
The recorded move for TFFP in the trading session of this news was +2.83%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
AUSTIN, Texas, Sept. 08, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that President and CEO Glenn Mattes will present a corporate overview at 23rd H.C. Wainwright Annual Global Investment Conference being held from September 13-15th, 2021.
Details on the presentation can be found below:
Presentation date: available on-demand starting at 7:00 a.m. ET on September 13, 2021
Webcast link: https://journey.ct.events/view/4a77d813-2d0d-4ffe-9b6d-920b5962e6e5
About TFF Pharmaceuticals
TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing, or TFF, technology platform. Early testing confirms that the TFF platform can significantly improve the solubility and absorption of poorly water-soluble drugs, a class of drugs that comprises approximately one-third of the major pharmaceuticals worldwide, thereby improving their pharmacokinetics. TFF Pharmaceuticals has two lead drug candidates: Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder. The Company plans to add to this pipeline by collaborating with large pharmaceutical partners. The TFF Platform is protected by 58 patents issued or pending in the US and internationally. To learn more about TFF Pharmaceuticals and its product candidates, visit the Company’s website at https://tffpharma.com.
Company Contacts:
Glenn Mattes
President and CEO
TFF Pharmaceuticals, Inc
gmattes@tffpharma.com
737-802-1973
Kirk Coleman
Chief Financial Officer
TFF Pharmaceuticals, Inc.
kcoleman@tffpharma.com
817-989-6358
Investor Relations Contact:
Corey Davis, Ph.D.
LifeSci Advisors
212-915-2577
cdavis@lifesciadvisors.com
Media Contact:
Gwendolyn Schanker
LifeSci Communications
269-921-3607
gschanker@lifescicomms.com
Source: TFF Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.